Search the Newsreel

AtriCure’s Profitability Inflection and 2026 Guidance Could Be A Game Changer For AtriCure (ATRC)

AtriCure, Inc. (ATRC) reported a significant profitability inflection in Q2 2026, moving from a net loss to positive earnings, achieving US$153.6 million in revenue and US$8.96 million in net income. The company issued full-year 2026 guidance forecasting US$602 million to US$610 million in revenue …

AtriCure to Participate at Upcoming Investor Conferences

MASON, Ohio, July 27, 2026--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in two upcoming investor conferences. AtriCure's …

ATRC|AtriCure Inc|Price:35.040|Chg%:+2.040

This article provides a detailed company profile of AtriCure Inc (ATRC), a medical technology company specializing in treatments for atrial fibrillation, LAA management, and post-operative pain. It outlines the company's business scope, financial data including its market cap and revenue sources, and lists key …

AtriCure Inc (ATRC) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of AtriCure Inc (ATRC) regarding its dividend and stock split history. It states that no dividends have been distributed by the company over the past five years. The page also presents current stock performance data and market capitalization for …

Atricure (ATRC) Receives a Buy from Stifel Nicolaus

Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Atricure (ATRC) with a $50.00 price target. This rating comes despite negative corporate insider sentiment and follows Atricure's latest earnings report showing increased revenue year-over-year. Another analyst from Piper Sandler also issued a Buy …

AtriCure (ATRC) Stock Faces Mixed Views As EPS Turnaround Tests Margin Narratives

AtriCure (ATRC) reported strong Q2 2026 results with a significant EPS turnaround and increased revenue, driven by improved margins and operating leverage rather than just revenue growth. While the profitability improvement supports bullish sentiment, the widely divergent valuation metrics (low DCF fair value vs. …

Earnings Flash (ATRC) AtriCure, Inc. Posts Q2 Adjusted EPS $0.18 per Share, vs. FactSet Est of $0.00

AtriCure, Inc. (ATRC) reported strong Q2 adjusted earnings per share of $0.18, significantly surpassing the FactSet estimate of $0.00. The company also announced Q2 revenue of $153.6 million, exceeding the FactSet estimate of $151.8 million, and provided an optimistic full-year 2026 adjusted EPS guidance …

AtriCure, Inc. Revenue Breakdown – NASDAQ:ATRC

AtriCure 2Q Net $8.96M >ATRC

This article states that AtriCure's second quarter net income was $8.96 million. The article headline seems to be the entire content provided.

AtriCure targets $602M-$610M 2026 revenue while raising adjusted EBITDA outlook to $85M-$89M

Earnings Call Insights: AtriCure (ATRC) Q2 2026 MANAGEMENT VIEW * "AtriCure delivered solid second quarter results with worldwide revenue of $154 million and growth of 13%." (CEO, President & Director Michael H. Carrel) Carrel said U.S. growth was "fueled by continued adoption" across pain …

AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say

AtriCure (ATRC) reported $153.6 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 12.8%. EPS of $0.18 for the same period compares to -$0.02 a year ago. The reported revenue represents a surprise of +1.39% over the Zacks Consensus …

AtriCure Releases Q2 2026 Financial Results

AtriCure, Inc. reported strong Q2 2026 financial results, with adjusted EPS of $0.18, significantly beating analyst estimates, and revenue of $153.6M, exceeding expectations. This performance represents a 12.8% increase in revenue year-over-year, driven by robust demand for their cardiac ablation technologies. The company provided …

Earnings call transcript: AtriCure tops Q2 2026 estimates, shares fall after hours

AtriCure Inc. reported strong second-quarter 2026 results, beating Wall Street expectations for both profit and revenue, primarily driven by growth in pain management, appendage management, and open ablation. Despite the positive financial performance and improved gross margins, the company's shares fell after hours, reflecting …

AtriCure Q2 Earnings Call Highlights

AtriCure reported strong Q2 2026 results with double-digit revenue growth and a return to GAAP profitability, driven by its pain management, appendage management, and open ablation franchises. The company raised its full-year adjusted EBITDA outlook, anticipating continued growth from these key areas while acknowledging …

AtriCure Reports Q2 2026 Results: Full Earnings Call Transcript

AtriCure (NASDAQ: ATRC) announced its Q2 2026 financial results, reporting worldwide revenue of $154 million, a 13% increase, and a U.S. revenue increase of 14%, driven by strong adoption of key products across its pain management, appendage management, and open ablation franchises. The company …

AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates

AtriCure (ATRC) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

ATRICURE ($ATRC) Releases Q2 2026 Earnings, Stock Rises

AtriCure reports Q2 2026 revenue $153.6M, net income $9.0M and adjusted EBITDA $27.3M

AtriCure announced strong financial results for Q2 2026, with revenue reaching $153.6 million, a 12.8% increase year over year, and a net income of $9.0 million. The company also reported an adjusted EBITDA of $27.3 million and robust cash generation, along with positive full-year …

AtriCure set to report earnings as competitive threat looms

AtriCure Inc. is preparing to report its second-quarter earnings, with analysts expecting an adjusted loss on strong revenue growth. The company faces new competition in the surgical left atrial appendage closure market from Edwards Lifesciences, but analysts believe AtriCure's established position and diverse product …

AtriCure (NASDAQ:ATRC) Posts Earnings Results

AtriCure: Q2 Earnings Snapshot

AtriCure (ATRC) Could Be 27% Undervalued Following Its Cardiac Device Growth Narrative

AtriCure (ATRC) is highlighted as potentially 27% undervalued, with a fair value estimate of $47.00 against a last close of $34.51. This valuation is driven by a narrative of rapid revenue growth from its innovative cardiac devices and strong market adoption. However, a different …

Citizens reiterates AtriCure stock rating on product growth outlook

Citizens has reaffirmed its Market Outperform rating and $52.00 price target for AtriCure Inc. (NASDAQ:ATRC), citing an expected 11% year-over-year sales growth in fiscal 2026, driven by new product launches and consistent product iteration. The company's strong revenue growth has been led by its …

AtriCure (ATRC) Proxy filing Summary

This article summarizes AtriCure's (ATRC) proxy filing for its 2026 Annual Meeting, scheduled virtually for May 18, 2026. Shareholders will vote on director elections, auditor ratification, amendments to equity plans, and executive compensation, with the Board recommending approval for all proposals. The Board's composition …

(ATRC) Movement Within Algorithmic Entry Frameworks

This article from Stock Traders Daily analyzes Atricure Inc. (NASDAQ: ATRC) using AI models to provide trading strategies and multi-timeframe signal analysis. It highlights strong near and mid-term sentiment but a weak long-term outlook for ATRC, with no clear price positioning signal identified. The …

Needham reiterates Buy on AtriCure stock after Q1 beat

AtriCure (ATRC) Reports Break-Even Earnings for Q1

AtriCure Q1 Earnings Call Highlights

AtriCure, Inc. (NASDAQ:ATRC) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

ATRICURE Earnings Results: $ATRC Reports Quarterly Earnings